At HKSTP, we connect stakeholders, foster collaboration and catalyse innovation.
lab & office space
DELIVERING SUCCESS
Partner companies’ success is our success. Their innovation is our business. We provide fertile ground to build Hong Kong’s innovation-driven future.
A LIVING LABORATORY
Hong Kong Science Park is a living laboratory where innovative technologies are tested and applied, and valuable data and feedback are collected to enable future innovation. It is also piloted as a smart region to further Hong Kong’s Smart City vision.
5 CLUSTERS AND 3 PLATFORMS
We leverage Hong Kong’s strengths in 5 technology clusters – Biomedical Technology, Electronics, Green Technology, Information and Communications Technology, Material and Precision Engineering, and facilitate the translation of R&D achievements into practical solutions for 3 major application platforms, namely Smart City, Healthy Ageing and Robotics.
SMART REGION, SMART CITY
In collaboration with the Chinese University of Hong Kong, we set up the smart region which is a “living lab” for piloting innovative solutions using technologies from the incubatees and partner companies in Science Park.
ENGAGING THE COMMUNITY
We engage the community to communicate the economic significance of innovation and technology and the possibilities they bring. We also support STEM (Science, Technology, Engineering and Mathematics) education and strive to build the city's STEM talent pool.
MAKEITHONGKONG
In HKSTP, we live and practise innovation and technology. We embrace people who have the courage to disrupt and cherish those who have the will to persevere.
GROOM TALENT
Vibrant Science Academy and Science Explorer are designed to instil interest in STEM subjects for young people through hands-on experience such as workshops and experiments.
WEEKLY HIGHLIGHTS
Dr. Cheng, a specialist in three specialties, has persisted in spending nearly 20 years chasing his dream of using innovative technologies to develop a cure for cancers. His efforts have led to the first drug entirely developed in Hong Kong to be given clinical trial approvals by both U.S. and UK regulatory authorities and has so far shown preliminary efficacy in controlling cancer growth in clinical trials.